Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Molnupiravir is authorized for people at high risk for severe COVID-19 when other treatment options are not available.
Paxlovid, which reduces the risk of hospitalization or death by about 90%, is expected to be a game-changer.
Molnupiravir, the first oral antiviral for COVID-19, reduces the risk of hospitalization or death if started within five days.
The new drugs must be used within a narrow window of time after developing symptoms.
Molnupiravir reduces severe illness and death, but it must be started within days after developing symptoms.
Paxlovid dramatically reduced the risk of severe illness and death, but it must be started soon after developing symptoms.
NIH-supported research will track effects of coronavirus infection on children over three years.
Post-exposure and pre-exposure prophylaxis could be a game-changer for immunocompromised people.
MIS-C is a rare but life-threatening complication in which a hyperactive immune system attacks a child’s body.
Treatment with interferon beta-1a plus the antiviral remdesivir was not superior to remdesivir alone.
Collins has led the NIH under three presidents over more than 12 years.
A steady stream of spurious claims about COVID-19 vaccines and treatments swirl around the public consciousness.
Experts call for heightened precautions and better, more intensive therapies for COVID-19 patients with weakened immune systems.
The government-wide effort aims to develop the next generation of COVID-19 treatments to prepare the U.S. to respond to future virus threats
Researchers used an airway-on-a-chip that mimics living lung tissue to screen approved drugs for use against SARS-CoV-2.
Molnupiravir, previously studied for hepatitis C, might be able to prevent or treat COVID-19 outside of a clinical setting.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.